The Clinical Utility of salivary oxytocin as a putatively surrogate early Risk Identification biomarker of nascent Metabolic Syndrome with and without prediabetes

24.Apr.2023

​Bulatova, N. R., Kasabri, V. N., Albsoul, A. M., Halaseh, L., & Suyagh, M. (2023). The Clinical Utility of salivary oxytocin as a putatively surrogate early Risk Identification biomarker of nascent Metabolic Syndrome with and without prediabetes.

https://doi.org/10.21203/rs.3.rs-2587738/v1

​